Amyl Raises Funds to Develop Therapies for Amyloidosis

Amyl Raises Funds to Develop Therapies for Amyloidosis

296616

Amyl Raises Funds to Develop Therapies for Amyloidosis

Amyl Therapeutics has raised €18.3 million — about $22.2 million — to develop its ClariTY technology platform to advance therapeutic candidates for familial amyloid polyneuropathy (FAP) and other forms of amyloidosis. “The ClariTY platform offers the unique opportunity to generate therapeutic candidates able to target all amyloid fibril deposits, a key cause of amyloidosis,” Pierre Vandepapelière, MD, PhD, Amyl’s CEO, chief medical officer, and cofounder, said in a press release. “We believe novel therapies with…

You must be logged in to read/download the full post.